Sagent制药(SGNT) 最新动态_F10_同花顺金融服务网

最新动态

每股收益： -0.17美元 [[[0,"-0.07"],[1,"-0.12"],[2,"-0.67"],[3,"-0.15"],[4,"-0.17"]],[[0,"2015\u4e2d\u62a5"],[1,"2015\u4e09\u5b63\u62a5"],[2,"2015\u5e74\u62a5"],[3,"2016\u4e00\u5b63\u62a5"],[4,"2016\u4e2d\u62a5"]],"\u7f8e\u5143"] 每股收益单位：美元查看明细>>	归母净利润： -550.5万美元同比增长-156.05% [[[0,"-215.00"],[1,"-394.50"],[2,"-2188.20"],[3,"-498.80"],[4,"-550.50"]],[[0,"2015\u4e2d\u62a5"],[1,"2015\u4e09\u5b63\u62a5"],[2,"2015\u5e74\u62a5"],[3,"2016\u4e00\u5b63\u62a5"],[4,"2016\u4e2d\u62a5"]],"\u4e07\u7f8e\u5143"] 净利润单位：万美元查看明细>>	每股净资产： 7.73美元 [[[0,"8.54"],[1,"8.32"],[2,"7.65"],[3,"7.72"],[4,"7.73"]],[[0,"2015\u4e2d\u62a5"],[1,"2015\u4e09\u5b63\u62a5"],[2,"2015\u5e74\u62a5"],[3,"2016\u4e00\u5b63\u62a5"],[4,"2016\u4e2d\u62a5"]],"\u7f8e\u5143"] 每股净资产单位：美元查看明细>>	净资产收益率ROE(平均)： -2.18% [[[0,"-1.98"],[1,"-2.18"]],[[0,"2016\u4e00\u5b63\u62a5"],[1,"2016\u4e2d\u62a5"]],""] 总资产报酬率(ROE) 单位：% 查看明细>>
稀释每股收益： -0.17美元 [[[0,"-0.07"],[1,"-0.12"],[2,"-0.67"],[3,"-0.15"],[4,"-0.17"]],[[0,"2015\u4e2d\u62a5"],[1,"2015\u4e09\u5b63\u62a5"],[2,"2015\u5e74\u62a5"],[3,"2016\u4e00\u5b63\u62a5"],[4,"2016\u4e2d\u62a5"]],"\u7f8e\u5143"] 稀释每股收益单位：美元查看明细>>	营业收入： 1.40亿美元同比增长-12.8% [[[0,"1.60"],[1,"2.35"],[2,"3.18"],[3,"0.68"],[4,"1.40"]],[[0,"2015\u4e2d\u62a5"],[1,"2015\u4e09\u5b63\u62a5"],[2,"2015\u5e74\u62a5"],[3,"2016\u4e00\u5b63\u62a5"],[4,"2016\u4e2d\u62a5"]],"\u4ebf\u7f8e\u5143"] 营业收入单位：万美元查看明细>>	每股现金流： -0.45美元 [[[0,"-0.05"],[1,"-0.39"],[2,"-0.23"],[3,"-0.51"],[4,"-0.45"]],[[0,"2015\u4e2d\u62a5"],[1,"2015\u4e09\u5b63\u62a5"],[2,"2015\u5e74\u62a5"],[3,"2016\u4e00\u5b63\u62a5"],[4,"2016\u4e2d\u62a5"]],"\u7f8e\u5143"] 每股现金流单位：美元查看明细>>	总资产收益率(ROA)： -1.55% [[[0,"-1.43"],[1,"-1.55"]],[[0,"2016\u4e00\u5b63\u62a5"],[1,"2016\u4e2d\u62a5"]],""] 总资产收益率(ROA) 单位：% 查看明细>>

注释：公司货币计价单位为美元

近期重要事件

2021-09-06	温馨提示：美股因劳工节，9月6日休市一天
2016-08-05	详情>> 股本变动：变动后总股本3291.05万股
2016-08-05	详情>> 业绩披露： 2016年中报每股收益-0.17美元,归母净利润-550.5万美元,同比去年增长-156.05%
2016-05-03	详情>> 业绩披露： 2016年一季报每股收益-0.15美元,归母净利润-498.8万美元,同比去年增长-163.36%
2016-04-29	股东大会：将于2016-06-08召开股东大会会议内容 ▼▲ 1. To elect as directors the nominees named in the Proxy Statement; 2. To ratify the retention of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016; 3. To approve the Sagent Pharmaceuticals, Inc. 2016 Incentive Compensation Plan; 4. To hold an advisory vote to approve the compensation of the named executive officers; 5. To transact any other business properly presented at the meeting or any adjournment thereof.
2016-03-07	详情>> 业绩披露： 2015年年报每股收益-0.67美元,归母净利润-2188.2万美元,同比去年增长-154.87%
2016-03-07	详情>> 业绩披露： 2013年年报每股收益1.01美元,归母净利润2959.40万美元,同比去年增长275.98%
2015-11-03	详情>> 业绩披露： 2015年三季报(累计)每股收益-0.12美元,归母净利润-394.5万美元,同比去年增长-139.01%
2015-08-04	详情>> 业绩披露： 2015年中报每股收益-0.07美元,归母净利润-215万美元,同比去年增长-126.26%
2015-05-05	详情>> 业绩披露： 2015年一季报每股收益-0.06美元,归母净利润-189.4万美元,同比去年增长-137%
2015-04-29	股东大会：将于2015-06-09召开股东大会会议内容 ▼▲ 1. To elect as Class I and Class III directors the nominees named in the Proxy Statement; 2. To ratify the retention of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2015; 3. An advisory vote to approve the compensation of the named executive officers; 4. To transact any other business properly presented at the meeting or any adjournment thereof.
2015-03-16	详情>> 业绩披露： 2014年年报每股收益1.25美元,归母净利润3988.10万美元,同比去年增长34.76%
2014-11-05	详情>> 业绩披露： 2014年三季报(累计)每股收益0.32美元,归母净利润1011.40万美元,同比去年增长-61.15%
2014-08-05	详情>> 业绩披露： 2014年中报每股收益0.26美元,归母净利润818.80万美元,同比去年增长-64.72%
2014-04-30	股东大会：将于2014-06-12召开股东大会会议内容 ▼▲ 1. To adopt and approve an amendment to our Certificate of Incorporation to declassify the Board of Directors and provide for the annual election of all directors, commencing with the 2016 Annual Meeting of Stockholders; 2. To elect as Class III directors the nominees named in the Proxy Statement each to serve a one-year term (if Proposal 1 is approved) or a three-year term (if Proposal 1 is not approved), and until their successors are duly elected and qualified, subject to earlier resignation, removal or death; 3. To ratify the retention of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2014; 4. To hold an advisory vote to approve the compensation of the named executive officers; 5. To transact any other business properly presented at the meeting or any adjournment thereof.
2013-04-30	股东大会：将于2013-06-13召开股东大会会议内容 ▼▲ 1. To elect as the Class II directors the nominees named in the Proxy Statement; 2. To ratify the retention of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2013; 3. To hold an advisory vote to approve the compensation of the named executive officers; 4. To transact any other business properly presented at the meeting or any adjournment thereof.
2012-08-09	复牌提示： 2012-08-09 07:00:14 停牌，复牌日期 2012-08-09 07:30:00

主营业务分析

注：通常在中报、年报时披露　

项目名称		营业收入(万美元)	收入比例(%)
按业务	病危护理	5934.4	42.54
	抗感染	5538.2	39.70
	肿瘤科	2479	17.77

项目名称		营业收入(万美元)	收入比例(%)
按业务	病危护理	2844.8	41.96
	抗感染	2803.2	41.35
	肿瘤科	1131.5	16.69

项目名称		营业收入(万美元)	收入比例(%)
按业务	抗感染	12851.7	40.38
	病危护理	12015.7	37.75
	肿瘤科	6962.2	21.87
按地区	Sagent美国分部	28761.2	90.36
按地区	加拿大（欧米茄部分）	3068.4	9.64

公司新闻

热点新闻更多>>

公司公告更多>>

同花顺个股页面 | 模拟炒股 | 股民学校 | 手机炒股| 联系我们

免责声明:本信息由同花顺金融研究中心提供，仅供参考，同花顺金融研究中心力求但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为准，同花顺金融研究中心不对因该资料全部或部分内容而引致的盈亏承担任何责任。用户个人对服务的使用承担风险。同花顺对此不作任何类型的担保。同花顺不担保服务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出错发生都不作担保。同花顺对在同花顺上得到的任何信息服务或交易进程不作担保。同花顺提供的包括同花顺理财的所有文章，数据，不构成任何的投资建议，用户查看或依据这些内容所进行的任何行为造成的风险和结果都自行负责，与同花顺无关。

【免责声明】本产品中的行情数据及资讯信息来源于第三方，长江证券不对收集数据的版权、真实性、准确性及传输过程中发生的传送错误承担法律责任。本内容仅供参考，不作为投资决策依据，长江证券不对因据此操作产生的盈亏承担任何责任。投资有风险，入市需谨慎。